Drug maker Pfizer (PFE) said late Tuesday that it will discontinue research on an experimental lung cancer drug after side effects led to an unexpected number of deaths in patients.
Pfizer said it was canceling enrollments for Phase 3 clinical trials for the drug, which was known as figitumumab. The compound was being used in treatment for a disease known non-adenocarcionoma, nonsmall-cell lung cancer.
According to Pfizer, the committee monitoring the clinical trials said in September it saw a “apparent imbalance” in serious side effects when using the drug, including fatalities.'
Read more...
No comments:
Post a Comment
Thanks for your comment it is much appreciated.